Rani Therapeutics is reportedly moving forward with an early-stage efficacy and safety study for its robotic pills and may be on its way toward the possibility of an IPO.
According to a report in Endpoints News, Rani, led by CEO Mir Imran who shared the story on LinkedIn, revealed that its RaniPill performed as expected with 58 healthy adult volunteers in distributing octreotide to treat hormonal disorder acromegaly.
Get the full story at our sister site, Drug Delivery Business News.